RxDoctor Payments Data

Stacy Brown

Family · Belpre, OHNPI 1497185284

Payments from drug & device makers

$3,085in general payments, 2019–2025

Across 155 payments — averaging $19.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$636
  • Astellas Pharma US Inc$513
  • 180 Medical, Inc.$281
  • Pfizer$208
  • Coloplast$155
  • Convatec Inc.$123
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$2,77190%
  • Education$31410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,085 in reported general payments places this provider in the 85th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$61,668
Medicare patients
610
Services billed
1,189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron405$251,957
GemtesaVibegron20$14,996
Methenamine Hippurate102$11,471
Mirabegron ErMirabegron16$9,699
Oxybutynin Chloride ErOxybutynin Chloride325$8,133
Tamsulosin Hcl455$7,451
Finasteride290$4,815
Potassium Citrate ErPotassium Citrate83$4,253
Tolterodine Tartrate ErTolterodine Tartrate42$4,107
Solifenacin Succinate28$3,271
Terazosin Hcl148$3,083
Estradiol44$2,911
Cephalexin236$2,600
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl14$1,657
Bethanechol Chloride18$1,317

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$513$251,957405 claims
Sumitomo Pharma America, Inc.Gemtesa$636$14,99620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,812 family providers in Ohio.

Other family in Belpre

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →